Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arhtritis

Genes and Immunity

Volumn 5, Issue 2, 2004, Pages 147-149

  Mattey, D L ^a   Nixon, N B ^a   Dawes, P T ^a   Ollier, W E R ^b   Hajeer, A H ^b  

^a Univ Hospital of N Staffordshire   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

HLA; Matrix metalloproteinase; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; ENZYME PRECURSOR; EPITOPE; GOLD; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; MATRIX METALLOPROTEINASE; METHOTREXATE; SALAZOSULFAPYRIDINE; STROMELYSIN;

ADULT; AGED; ALLELE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; JOINT DESTRUCTION; JOINT FUNCTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DNA PRIMERS; GENOTYPE; GREAT BRITAIN; HUMANS; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); STATISTICS, NONPARAMETRIC;

EID: 3242808141     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364050     Document Type: Article

References (24)

1. Docherty AJP, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis 1990; 49: 469-479.
2. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991; 34: 1076-1084.
3. Walakovits L, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992; 35: 35-42.
4. Nagase H. Activation mechanism of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
5. Cowell S, Knauper V, Stewart ML et al. Induction of matrix metalloproteinase activation cascades based on membrane type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase-3. Biochem J 1998; 331: 453-458.
6. Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994; 53: 768-772.
7. Zucker S, Lysik RM, Zarrabi MH et al. Elevated plasma stromelysin levels in arthritis. J Rheumatol 1994; 21: 2329-2333.
8. Keyszer G, Lambiri I, Nagel R et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1(TIMP-1) and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999; 26: 251-258.
9. Cheung NT, Dawes PT, Poulton KV, Ollier WER, Taylor DJ, Mattey DL. High serum levels of proMMP-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 882-887.
10. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptiblity to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213.
11. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-215.
12. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055-13060.
13. Ye S, Whatling C, Watkins H, Henney A. Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett 1999; 450: 268-272.
14. Constantin A, Lauwers-Cances V, Naxaux F et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms. Arthritis Rheum 2002; 46: 1754-1762.
15. Schwarz A, Haberbosch W, Tillmanns H, Gardemann A. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 2002; 18: 121-128.
16. van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extra-articular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-873.
17. del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745.
18. Wallberg Jonsson SW, Backman C, Johnson O et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001; 28: 2597-2602.
19. Kumeda Y, Inaba M, Goto H et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489-1497.
20. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
21. Larsen A, Dale K, Eck M. Radiographic evaluation of rheumatoid arthitis and related conditions by standard reference films. Acta Radiol (Diagn Stockh) 1977; 18: 481-491.
22. Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994; 21: 1808-1813.
23. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-145.
24. Gnasso A, Motti C, Irace C et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600-1605.